Taken together with the imeglimin-mediated increase in the amount of secreted insulin and reduction in apoptotic β-cell death, our findings suggest that imeglimin is beneficial for maintaining mQC in diabetic β-cells and preserving β-cell function and euglycemia in T2D patients. Here, INS is linked to type 2 diabetes mellitus.